Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Treasury Shares (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Treasury Shares for 7 consecutive years, with $69486.0 as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 61.33% to $69486.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $69486.0 through Dec 2025, up 61.33% year-over-year, with the annual reading at $69486.0 for FY2025, 61.33% up from the prior year.
  • Treasury Shares for Q4 2025 was $69486.0 at Fulcrum Therapeutics, down from $69.5 million in the prior quarter.
  • The five-year high for Treasury Shares was $70.7 million in Q2 2025, with the low at $420.0 in Q1 2022.
  • Average Treasury Shares over 5 years is $9.4 million, with a median of $76718.0 recorded in 2022.
  • The sharpest move saw Treasury Shares crashed 80.9% in 2021, then skyrocketed 97577.75% in 2025.
  • Over 5 years, Treasury Shares stood at $32837.0 in 2021, then soared by 133.63% to $76718.0 in 2022, then dropped by 2.22% to $75017.0 in 2023, then plummeted by 42.58% to $43072.0 in 2024, then soared by 61.33% to $69486.0 in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $69486.0, $69.5 million, and $70.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.